RG Clinical Trials and Prognosis Research

In collaboration with our partners in the medical field, our research group has been responsible for the biometric management of clinical trials for the past 15 years. In addition, we are engaged in the development and validation of prognostic models. The most successful of these models is the ELTS score, which is used to estimate the survival of patients with chronic myeloid leukemia from the time of diagnosis. Its use is recommended by the European LeukemiaNet.

Lead

Markus Pfirrmann
Prof. Dr. rer. biol. hum. Markus Pfirrmann, M.Sc.

Lead of RG Clinical Trials and Prognosis Research; Acting Deputy Director of the Department of Medical Biometry and of the IBE

Team

Name Title Position
Albeer, Ali M.Sc. Scientific Research Associate
Brenninger-Lang, Thomas M.Sc. Scientific researcher
Kohn, Denise   Data Manager
Schmitt, Annett Dipl. Biochemikerin Data Manager

Areas of work

As part of its biometric activities, the research group focuses intensively on developing the statistical components of study protocols. Particular emphasis is placed on sample size estimation, adjustment methods for multiple hypothesis testing, and the development of analytical methods that go beyond standard procedures.

The goal of many projects has been and continues to be the investigation of potential prognostic factors for various therapeutic outcome parameters. In particular, the availability of large datasets of imatinib-treated patients with chronic myeloid leukemia (CML)—made possible by the EUTOS Registry—enabled the development of two recognized and validated prognostic systems: the EUTOS score for predicting remission success at 18 months and the ELTS score for predicting long-term survival.

In addition, a prognostic score has also been proposed for patients with acute myeloid leukemia (AML).

The ELTS score has been independently validated multiple times in several countries (Sweden, France, Italy, and China). Furthermore, the score was proposed as the prognostic model to be used at the time of diagnosis for CML patients in the recommendations of the “European LeukemiaNet” (ELN) (Hochhaus et al., European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia, Leukemia, 2020 and Apperley et al., 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia, Leukemia, 2025).

The primary outcome measures for most research questions in the field of leukemia are event-time variables. Accordingly, the research group follows methodological developments in the field of survival analysis—specifically the consideration of competing events—with particular interest. Various publications have addressed the Cox-Cure model, the Fine-Gray model, the modeling of multiple stages, and relative survival probabilities.

The research group is responsible for the biometric management of three ongoing studies on chronic myeloid leukemia (CML—the TIGER, DasaHIT, and FASCINATION studies) as well as a study on the efficacy of multi-specific T-cell administration against chemotherapy-refractory viral infections following allogeneic stem cell transplantation (TRACE study). Another study in the field of CML is in the planning stages.

In addition to the clinical trials mentioned above, data from six CML registry studies are being analyzed to address various research questions. The registries include the NAUT study, the PONTrack study, the CML Treatment-Free Response (TFR) Registry, the International CML Genomics Alliance study, the EURO-SKI study, and the EUTOS study. The collaboration agreement for two additional studies is nearing completion.

In 2012, the working group began programming electronic case report forms (eCRFs). Since then, eCRFs have been set up for 7 studies. Data are currently being collected for the FASCINATION study, the NAUT study, and the PONTrack study. The design and programming of two new eCRFs will begin in 2026.

Current Studies and Projects

Name of projectDescription
CML V TIGER-StudyA prospective, randomized, open-label, multicenter therapeutic study comparing nilotinib with and without interferon as induction therapy, and nilotinib versus interferon as maintenance therapy for the treatment of chronic myeloid leukemia (CML).
DasaHIT-StudyA prospective, randomized, open-label, multicenter dasatinib dose-optimization study to evaluate the tolerability and efficacy of medication taken on 5 out of 7 days of the week versus daily dosing in patients with CML.
FASCINATION-StudyProspective, non-randomized, open-label, multicenter study of deep molecular response in CML patients treated with a combination of an established tyrosine kinase inhibitor and asciminib.
TRACE-StudyA prospective, randomized, double-blind, placebo-controlled, multicenter study of the efficacy of multi-specific T-cell infusion against chemo-refractory viral infections following allogeneic stem cell transplantation.
NAUT-StudyProspective, open-label, multicenter registry study to investigate the feasibility of discontinuing therapy again in CML patients who relapsed after the first discontinuation of therapy but subsequently achieved deep remission following renewed nilotinib therapy lasting at least two years.
PONTrack-StudyProspective, open-label, multicenter registry study on deep molecular response in CML patients who have received 2 years of ponatinib treatment.
CML-TFR-RegistryA registry for the prospective assessment of treatment-free molecular remission status in CML, with the aim of investigating prognostic factors.
International CML Genomics AllianceGlobal genomic data to evaluate the clinical relevance of pathogenic variants at the time of diagnosis of CML in the chronic phase with regard to events such as the occurrence of BCR::ABL1 kinase domain mutations, disease progression, or death.
ESTIMATION-StudyRegistry for the prospective assessment of molecular remission success in CML patients with the T315I mutation who are being treated with asciminib.
EURO-SKI-StudyRegistry for prognostic research on the maintenance of molecular remission in CML patients following discontinuation of therapy.
ELN/EUTOS-RegistryA registry for prognostic research on prospectively enrolled CML patients treated predominantly with imatinib and their outcomes over the course of therapy.